作者: G. Landoni , D. Poli , T. Bove
DOI: 10.1007/S11789-006-0046-5
关键词: Angiology 、 Intensive care medicine 、 Fenoldopam Mesylate 、 Randomized controlled trial 、 Evidence-based medicine 、 Renal replacement therapy 、 Diuretic 、 Cardiac surgery 、 Anesthesia 、 Medicine 、 Fenoldopam
摘要: Fenoldopam mesylate is a useful antihypertensive and diuretic drug. In this review, we examine the evidence based medicine wheter to use fenoldopam in cardiac surgery patients and/or critically ill with or at risk for acute renal failure (ARF). We conclude that from published studies it seems could be beneficial if prolonged infusion performed starting early process of ARF patients. Unfortunately there still virtually no definitive efficacy, especially A large, multicenter, randomized, controlled trial (RCT) needed confirm promising but conflicting findings